Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13591170 | 0.89 | CYP3A4 (0.52) | — | |
| SCHEMBL14091145 | 0.85 | ACKR3 (0.49) | ACKR3 | |
| SCHEMBL13391102 | 0.83 | ACKR3 (0.51) | ACKR3 | |
| SCHEMBL14188123 | 0.78 | CYP3A4 (0.48) | — | |
| SCHEMBL14215577 | 0.78 | CYP3A4 (0.48) | — | |
| SCHEMBL8230921 | 0.78 | CNR1 (0.60) | — | |
| SCHEMBL13391188 | 0.77 | CYP3A4 (0.55) | — | |
| SCHEMBL8418718 | 0.77 | ACKR3 (0.55) | ACKR3 | |
| SCHEMBL14091095 | 0.76 | CYP3A4 (0.52) | — | |
| SCHEMBL13409072 | 0.76 | CYP3A4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | ACKR3 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.